Trimethobenzamide (oral)

Trimethobenzamide (oral)
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Trimethobenzamide (oral) is an antiemetic that is FDA approved for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.. Common adverse reactions include hypotension, diarrhea, xerostomia, and somnolence.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Postoperative nausea and vomiting

• Trimethobenzamide hydrochloride capsules, USP are indicated for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.

Dosing information

• Dosage should be adjusted according to the indication for therapy, severity of symptoms and the response of the patient.

Geriatric Patients

• Dose adjustment such as reducing the total dose administered at each dosing or increasing the dosing interval should be considered in elderly patients with renal impairment (creatinine clearance ≤70 mL/min/1.73m2). Final dose adjustment should be based upon integration of clinical efficacy and safety considerations.

Patients with Renal Impairment

• In subjects with renal impairment (creatinine clearance ≤70 mL/min/1.73m2), dose adjustment such as reducing the total dose administered at each dosing or increasing the dosing interval should be considered.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Trimethobenzamide (oral) in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Trimethobenzamide (oral) in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding FDA-Labeled Use of Trimethobenzamide (oral) in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Trimethobenzamide (oral) in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Trimethobenzamide (oral) in pediatric patients.

Contraindications

• Use of any dosage form in patients with known hypersensitivity to trimethobenzamide is contraindicated.

Warnings

• Caution should be exercised when administering trimethobenzamide hydrochloride capsules, USP to children for the treatment of vomiting. Antiemetics are not recommended for treatment of uncomplicated vomiting in children and their use should be limited to prolonged vomiting of known etiology. There are two principal reasons for caution

• The extrapyramidal symptoms which can occur secondary to trimethobenzamide hydrochloride capsules, USP may be confused with the central nervous system signs of an undiagnosed primary disease responsible for the vomiting, e.g., Reye's syndrome or other encephalopathy.
• It has been suspected that drugs with hepatotoxic potential, such as trimethobenzamide hydrochloride capsules, USP, may unfavorably alter the course of Reye's syndrome. Such drugs should therefore be avoided in children whose signs and symptoms (vomiting) could represent Reye's syndrome.
• Trimethobenzamide hydrochloride capsules, USP may produce drowsiness. Patients should not operate motor vehicles or other dangerous machinery until their individual responses have been determined.

Precautions

• During the course of acute febrile illness, encephalitides, gastroenteritis, dehydration and electrolyte imbalance, especially in children and the elderly or debilitated, CNS reactions such as opisthotonos, convulsions, coma and extrapyramidal symptoms have been reported with and without use of trimethobenzamide hydrochloride capsules, USP or other antiemetic agents. In such disorders caution should be exercised in administering trimethobenzamide hydrochloride capsules, USP, particularly to patients who have recently received other CNS-acting agents (phenothiazines, barbiturates, belladonna derivatives). Primary emphasis should be directed toward the restoration of body fluids and electrolyte balance, the relief of fever and relief of the causative disease process. Overhydration should be avoided since it may result in cerebral edema.
• The antiemetic effects of trimethobenzamide hydrochloride capsules, USP may render diagnosis more difficult in such conditions as appendicitis and obscure signs of toxicity due to overdosage of other drugs.

General

• Adjustment of Dose in Renal Failure
• A substantial route of elimination of unchanged trimethobenzamide is via the kidney. Dosage adjustment should be considered in patients with reduced renal function including some elderly patients

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Trimethobenzamide (oral) in the drug label.

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Trimethobenzamide (oral) in the drug label.

Drug Interactions

There is limited information regarding Trimethobenzamide (oral) Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

• Trimethobenzamide hydrochloride was studied in reproduction experiments in rats and rabbits and no teratogenicity was suggested. The only effects observed were an increased percentage of embryonic resorptions or stillborn pups in rats administered 20 mg and 100 mg/kg and increased resorptions in rabbits receiving 100 mg/kg. In each study these adverse effects were attributed to one or two dams. The relevance to humans is not known. Since there is no adequate experience in pregnant or lactating women who have received this drug, safety in pregnancy or in nursing mothers has not been established.

Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Trimethobenzamide (oral) in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Trimethobenzamide (oral) during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Trimethobenzamide (oral) with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Trimethobenzamide (oral) with respect to pediatric patients.

Geriatic Use

• The clearance of trimethobenzamide is not known in patients with renal impairment. However, it may be advisable to consider reduction in the dosing of trimethobenzamide in elderly patients with renal impairment considering that a substantial amount of excretion and elimination of trimethobenzamide occurs via the kidney and that elderly patients may have various degrees of renal impairment.
• Clinical studies of trimethobenzamide hydrochloride did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Although there are studies reported in the literature that included elderly patients >65 years old with younger patients, it is not known if there are differences in efficacy or safety parameters for elderly and non-elderly patients treated with trimethobenzamide. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
• This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Gender

• Systemic exposure to trimethobenzamide was similar between men (N=40) and women (N=28).

Race

• Pharmacokinetics appeared to be similar for Caucasians (N=53) and African Americans (N=12).

Renal Impairment

• The clearance of trimethobenzamide is not known in patients with renal impairment. However, it may be advisable to consider reduction in the dosing of trimethobenzamide in patients with renal impairment considering that a substantial amount of excretion and elimination of trimethobenzamide occurs via the kidney.

Hepatic Impairment

There is no FDA guidance on the use of Trimethobenzamide (oral) in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Trimethobenzamide (oral) in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Trimethobenzamide (oral) in patients who are immunocompromised.

Administration and Monitoring

Administration

• Intramuscular

Monitoring

There is limited information regarding Monitoring of Trimethobenzamide (oral) in the drug label.

IV Compatibility

There is limited information regarding IV Compatibility of Trimethobenzamide (oral) in the drug label.

Overdosage

There is limited information regarding Chronic Overdose of Trimethobenzamide (oral) in the drug label.

Pharmacology

Trimethobenzamide (oral)
Systematic (IUPAC) name
N-{[4-(2-dimethylaminoethoxy)phenyl]methyl}- 3,4,5-trimethoxy-benzamide
Identifiers
CAS number	138-56-7
ATC code	R06AA10
PubChem	5577
DrugBank	DB00662
Chemical data
Formula	Template:OrganicBox atomTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox
Mol. mass	388.458 g/mol
SMILES	eMolecules & PubChem
Pharmacokinetic data
Bioavailability	60-100%
Metabolism	?
Half life	7 to 9 hours (mean)
Excretion	urine (30-50%), faeces
Therapeutic considerations
Pregnancy cat.	C(US)
Legal status	[[Prescription drug|Template:Unicode-only]](US)
Routes	Oral, rectal, intramuscular

Mechanism of Action

• The mechanism of action of trimethobenzamide hydrochloride capsules, USP as determined in animals is obscure, but may involve the chemoreceptor trigger zone (CTZ), an area in the medulla oblongata through which emetic impulses are conveyed to the vomiting center; direct impulses to the vomiting center apparently are not similarly inhibited. In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against emesis induced by intragastric copper sulfate.

Structure

• Chemically, trimethobenzamide HCl is N-[p-[2-(dimethylamino)ethoxy]benzyl]-3,4,5-trimethoxybenzamide monohydrochloride. It has a molecular weight of 424.93 and the following structural formula:

This image is provided by the National Library of Medicine.

• Each capsule for oral use contains trimethobenzamide hydrochloride equivalent to 300 mg.

• Inactive Ingredients: FDA/E172 Red Iron Oxide, gelatin, magnesium stearate, microcrystalline cellulose, sodium starch glycolate and titanium dioxide. The imprinting ink contains D&C *Yellow #10 Lake, FD&C Blue #1, FD&C Blue #2, FD&C Red #40, Iron Oxide Black, propylene glycol and shellac glaze.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Trimethobenzamide (oral) in the drug label.

Pharmacokinetics

• The pharmacokinetics of trimethobenzamide have been studied in healthy adult subjects. Following administration of 200 mg (100 mg/mL) trimethobenzamide hydrochloride I.M. injection, the time to reach maximum plasma concentration (Tmax) was about half an hour, about 15 minutes longer for trimethobenzamide hydrochloride 300 mg oral capsule than an I.M. injection. A single dose of trimethobenzamide hydrochloride 300 mg oral capsule provided a plasma concentration profile of trimethobenzamide similar to trimethobenzamide hydrochloride 200 mg I.M. The relative bioavailability of the capsule formulation compared to the solution is 100%. The mean elimination half-life of trimethobenzamide is 7 to 9 hours. Between 30 – 50% of a single dose in humans is excreted unchanged in the urine within 48–72 hours. The major pathway of trimethobenzamide metabolism is through oxidation resulting in the formation of trimethobenzamide N-oxide metabolite. The pharmacologic activity of this major metabolite has not been evaluated.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Trimethobenzamide (oral) in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Trimethobenzamide (oral) in the drug label.

How Supplied

There is limited information regarding Trimethobenzamide (oral) How Supplied in the drug label.

Storage

There is limited information regarding Trimethobenzamide (oral) Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Trimethobenzamide (oral) |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Trimethobenzamide (oral) |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Trimethobenzamide (oral) in the drug label.

Precautions with Alcohol

• Concomitant use of alcohol with trimethobenzamide hydrochloride capsules, USP may result in an adverse drug interaction.

Brand Names

• Benzacot
• Tigan
• Tebamide
• Arrestin
• Stemetic
• Ticon
• Tribenzagan

Look-Alike Drug Names

There is limited information regarding Trimethobenzamide (oral) Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

{{#subobject:

 |Label Page=Trimethobenzamide (oral)
 |Label Name=Trimethobenzamide04.png

}}

{{#subobject:

 |Label Page=Trimethobenzamide (oral)
 |Label Name=Trimethobenzamide05.png

}}